Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

The benefit was driven by a reduction in worsening heart failure events, which occurred in 8.0% and 14.2% of the tirzepatide and placebo groups, respectively (HR, 0.54; 95% CI, 0.34 - 0.85).

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

On the primary endpoints of the study, combined cardiovascular mortality and worsening heart failure events (α = 0.04) were determined in 36 patients (9.9%) in the tirzepatide group, whereas in ...

The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening heart failure events in adults with ...

Treatment with tirzepatide was associated with a reduction in the risk of heart failure (HF) outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

Tirzepatide showed a 38% reduction in the risk of heart failure outcomes, assessed as a composite endpoint, compared to placebo. Risk of hospitalization for heart failure was reduced by 56%.

"Cardiometabolic diseases, such as heart failure and obesity, are closely linked and often coexist. New approaches are needed to address the interrelated nature of these diseases. At Lilly, we ...